Drugs / genetically engineered lymphocyte therapy
genetically engineered lymphocyte therapy
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00621452 | Aug 2007 → Jan 2014 | MALT lymphoma, Waldenstrom macroglobulinemia, chronic lymphocytic leukemia/small lymphocytic lymphoma, mantle cell lymphoma +2 | Fred Hutchinson Cancer Center | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | genetically engineered lymphocyte therapy | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00621452 ↗ |
| Modality | Cell therapy | “T cells containing CARs with costimulatory domains exhibit improved activity against tumors” PMID 22308288 ↗ Feb 2012 |
| Route | Intravenous | “autologous CD20-specific T-cells IV over 30 minutes” NCT00621452 ↗ |